GE HealthCare to Acquire SOFIE Biosciences

Oct. 5, 2026 — GE HealthCare has announced a definitive agreement to acquire SOFIE Biosciences, a U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, at which time SOFIE Biosciences will become part of GE HealthCare’s PDx segment.

The acquisition of SOFIE Biosciences establishes a footprint for GE HealthCare in the time-critical "final mile" of U.S. PET radiopharmaceutical supply, while also enabling PDx to participate in other high growth areas outside its own product portfolio. With a U.S. network of 15 CMO sites operating 21 cyclotrons, and a theranostics-focused Contract Development and Manufacturing Organization (CDMO) site, this acquisition broadens GE HealthCare's footprint in the U.S. radiopharmaceutical industry, while driving reliable patient access to novel radiopharmaceuticals. It also further enables GE HealthCare’s ability to provide solutions along every step of the theranostics pathway, from cyclotrons to imaging technology, digital workflow tools and radiotherapeutics infrastructure.

“The PET radiopharmaceutical market is expanding rapidly with the introduction of innovative radiotracers and advances in precision care, including the growing adoption of targeted therapies. As part of GE HealthCare, SOFIE Biosciences is expected to grow in the low double digits, and enables us to participate across the radiopharmaceutical value stream, meeting customer demand through a mix of GE HealthCare owned and partner facilities. SOFIE Biosciences has a highly skilled team with deep expertise serving U.S. customers, including manufacturing our Flyrcado (flurpiridaz F18 injection) product,” said Kevin O'Neill, President & CEO of the PDx segment at GE HealthCare.  

PET radiopharmaceuticals are used in precision medicine to visualize metabolic and molecular activity and, increasingly, to deliver targeted therapies across a range of disease areas. F18 labeled PET radiopharmaceuticals have a 110-minute half-life, with PET CMOs playing a crucial role in enabling timely and reliable patient access, both to existing and pipeline products. Industry-wide, the radiopharmaceutical pipeline is growing rapidly, with approximately 20 PET radiotracers and over 30 radiotherapeutics currently under development.¹ These include SOFIE Biosciences’ Phase III F18 Fibroblast Activation Protein Inhibitor (FAPI) asset, FAPI-74, for which GE HealthCare already holds outside-of-U.S. rights. FAPI has the potential to further expand an already fast-growing global PET imaging market, and is showing strong potential for diagnostic and theranostic use across a range of oncologic and non-oncologic indications. 

GE HealthCare will continue to drive and expand access to its existing proprietary F18 radiopharmaceutical products, while advancing its pipeline of new products, both through SOFIE Biosciences, and PDx’s other established CMO partners across the U.S. 

Serving SOFIE Biosciences Customers

Following the transaction close, SOFIE Biosciences will continue to operate as an independent manufacturing partner to its customers, supplying its existing product portfolio, including products from other leading radiopharmaceutical providers.

Patrick Phelps, SOFIE Biosciences co-founder, President & CEO, said, “As demand continues to increase for F18 products, and pipelines for new diagnostics and therapeutics continue to expand, joining GE HealthCare marks an exciting step in our journey as a leading U.S. CMO. With Trilantic North America’s support, we have significantly expanded our capabilities and scale, and we share GE HealthCare’s ambition to improve patient outcomes by delivering on the promise of radiopharmaceuticals as we look ahead to our next phase of growth.”

Ted Rosenwasser, Partner, Trilantic North America, said, "We are incredibly proud of what Patrick and the SOFIE Biosciences team have accomplished during our partnership. SOFIE Biosciences has grown significantly, investing in its network and manufacturing capabilities to help meet growing demand and enable increased and reliable patient access to critical products. GE HealthCare's legacy and global expertise make it a natural partner to support SOFIE Biosciences’ continued growth and help expand access for U.S. patients to novel diagnostic and therapeutic radiopharmaceuticals.”

GE HealthCare’s Pharmaceutical Diagnostics segment is a global leader in imaging agents used to support 140 million procedures in 2025, equivalent to four patient procedures every second. For more than 40 years, GE HealthCare's imaging agents have been routinely used across care pathways to support diagnosis. 

References

1. MEDraysintell Report, 2025 Edition